Brain Tumors

Latest Articles

Zotiraciclib Granted Orphan Drug Designation for Treatment of Glioma

The Food and Drug Administration (FDA) has granted Orphan Drug Designation to zotiraciclib (Adastra Pharmaceuticals) for the treatment of glioma.

Visual Dysfunction an Important Element in Morbidity of Pituitary Adenoma

Visual symptoms are a vital component of the morbidity encountered in patients with pituitary adenoma, can present at all stages of the disease, and may negatively affect daily activities and overall quality of life, a new review claims.

Non-melanoma Skin Cancers Are Less Likely to be Treated in Elderly Patients

Unlike previous studies, the researchers found that in their practice, no-treatment rates between elderly and nonelderly patients with biopsy-proven NMSCs were significantly different.

Outcomes Poor Years After Radiation for Pediatric Glioma Survivors

Survivors of childhood low-grade gliomas treated with radiotherapy have poorer neuropsychological and socioeconomic-status outcomes.

Computer-Assisted Diagnosis Aids Detection of Glioma Growth

Computer-assisted diagnosis (CAD) can help physicians detect growth of low-grade gliomas.

Phase 3 Study of Investigative Glioblastoma Treatment Halted

AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.

Lifetime Risk for Brain Metastasis Increased in Elderly With Some Common Cancers

Highest incidence seen for patients with non-small cell lung cancer and triple-negative breast cancer

Contrast-Enhanced MRI Characterization of Brain Cancers

According to researchers, neovascularization is more common in glioblastoma, and extravasation is more common in primary CNS lymphoma.

Combining CAR-T and BiTE in Models of Glioblastoma Multiforme

This study involved the engineering of CAR-T cells specific for the EGFRvIII antigen to also secrete bispecific T cell engagers (BiTEs) against wild-type EGFR.

Neoadjuvant PD-1 Blockade Seems Effective in Glioblastoma

Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma.